Modalis Therapeutics Corporation [4883.T]
TOKYO, Apr 27 (Pulse News Wire) – Modalis Therapeutics Corporation (4883.T) announced plans to sell idle assets owned by its subsidiary, Modalis Therapeutics Inc., located in Waltham, Massachusetts. The sale includes machinery and equipment used for process development.
The estimated gain from the transaction is approximately ¥17.5 million. The board approved the decision , with the contract expected to be finalized on April 30, 2026. Asset transfer is scheduled for May 8, 2026. The company stated that the sale reflects efficient resource management and asset optimization within the group.
The transferred assets are not due to overinvestment or changes in business strategy but rather part of a rational replacement and optimization process driven by developmental progress. Details of the buyer remain undisclosed at their request. There are no significant capital, personal, or trading relationships between the seller and the buyer. The anticipated special profit from this transaction will be recorded in the December 2026 fiscal year's results.
The company expects the impact on performance to be minor, contingent upon further developments requiring disclosure.
🟡 Confidence: Standard AI-translated content.